# Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders

> **NCT02540538** · PHASE1 · COMPLETED · sponsor: **Maastricht University Medical Center** · enrollment: 34 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** HBVaxPro
- **BIOLOGICAL:** HBAI20

## Key facts

- **NCT ID:** NCT02540538
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2018-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02540538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02540538, "Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02540538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*